Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats

Metabolism: Clinical and Experimental

Volumn 46, Issue 9, 1997, Pages 981-983

  Fujii, Mitsuhiro ^a   Takemura, Reiji ^a   Yamaguchi, Makiko ^a   Hasegawa, Goji ^a   Shigeta, Hirofumi ^a   Nakano, Koji ^a   Kondo, Motoharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; INSULIN; PROTEIN KINASE C; STREPTOZOCIN; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0030823445     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90264-X     Document Type: Article

References (11)

1. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
2. Suter S, Nolan JJ, Wallance P, et al: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
3. Kellerer M, Kroder G, Tippmer S, et al: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblast. Diabetes 43:447-453, 1994
4. Bahr M, Spelleken M, Bock M, et al: Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 39:766-774, 1996
5. Larkins RG, Dunlop ME: The link between hyperglycemia and diabetic nephropathy. Diabetologia 35:499-504, 1992
6. Goldfarb S, Ziyadeh FN, Kern EFO, et al: Effects of polyolpathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 40:465-471, 1991
7. Soulis T, Cooper ME, Vranes D, et al: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634, 1996
8. Ishii H, Jirousek MR, Koya D, et al: Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272:728-731, 1996
9. Yoshioka S, Nishino H, Shiraki T, et al: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
10. Tilton RG, Williamson JR: Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 7:35-39, 1991
11. Pfeiffer A, Schatz H: Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 103:7-14, 1995